首页 | 本学科首页   官方微博 | 高级检索  
检索        


Prion protein amyloidosis with divergent phenotype associated with two novel nonsense mutations in PRNP
Authors:Casper Jansen  Piero Parchi  Sabina Capellari  Ad J Vermeij  Patrizia Corrado  Frank Baas  Rosaria Strammiello  Willem A van Gool  John C van Swieten  Annemieke J M Rozemuller
Institution:1. Dutch Surveillance Centre for Prion Diseases, University Medical Centre Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
2. Dipartimento di Scienze Neurologiche, Università di Bologna, Via Foscolo 7, 40123, Bologna, Italy
3. Department of Neurology, Maxima Medical Centre, Ds. Th. Fliednerstraat 1, 5600 PD, Eindhoven, The Netherlands
4. Department of Neurogenetics, Academic Medical Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
5. Department of Neurology, Academic Medical Centre, Meibergdreef 9, 1105 AZ, Amsterdam, The Netherlands
6. Department of Neurology, Erasmus University Medical Centre, ‘s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
7. Netherlands Brain Bank, NIN, Meibergdreef 47, 1105 BA, Amsterdam, The Netherlands
8. Department of Pathology, VU University Medical Center, de Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands
Abstract:Stop codon mutations in the gene encoding the prion protein (PRNP) are very rare and have thus far only been described in two patients with prion protein cerebral amyloid angiopathy (PrP-CAA). In this report, we describe the clinical, histopathological and pathological prion protein (PrPSc) characteristics of two Dutch patients carrying novel adjacent stop codon mutations in the C-terminal part of PRNP, resulting in either case in hereditary prion protein amyloidoses, but with strikingly different clinicopathological phenotypes. The patient with the shortest disease duration (27 months) carried a Y226X mutation and showed PrP-CAA without any neurofibrillary lesions, whereas the patient with the longest disease duration (72 months) had a Q227X mutation and showed an unusual Gerstmann-Sträussler-Scheinker disease phenotype with numerous cerebral multicentric amyloid plaques and severe neurofibrillary lesions without PrP-CAA. Western blot analysis in the patient with the Q227X mutation demonstrated the presence of a 7 kDa unglycosylated PrPSc fragment truncated at both the N- and C-terminal ends. Our observations expand the spectrum of clinicopathological phenotypes associated with PRNP mutations and show that a single tyrosine residue difference in the PrP C-terminus may significantly affect the site of amyloid deposition and the overall phenotypic expression of the prion disease. Furthermore, it confirms that the absence of the glycosylphosphatidylinositol anchor in PrP predisposes to amyloid plaque formation.
Keywords:
本文献已被 SpringerLink 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号